Earnings summaries and quarterly performance for Xilio Therapeutics.
Executive leadership at Xilio Therapeutics.
Board of directors at Xilio Therapeutics.
Research analysts covering Xilio Therapeutics.
Recent press releases and 8-K filings for XLO.
Xilio Therapeutics Announces Pricing of Underwritten Offering
XLO
New Projects/Investments
- Xilio Therapeutics, Inc. announced the pricing of an underwritten offering of 74,780,300 pre-funded warrants at $0.5349 per pre-funded warrant on February 11, 2026.
- The offering is expected to generate approximately $40.0 million in gross proceeds and $37.1 million in net proceeds.
- The net proceeds will be used to advance product candidates, for working capital requirements, and other general corporate purposes.
- The financing was led by Coastlands Capital and included participation from Gilead Sciences, Inc., OrbiMed, and Perceptive Advisors. The offering is expected to close on or about February 13, 2026.
Feb 12, 2026, 9:51 PM
Xilio Therapeutics Prices Underwritten Offering of Pre-Funded Warrants
XLO
New Projects/Investments
- Xilio Therapeutics announced the pricing of an underwritten offering of 74,780,300 pre-funded warrants to purchase common stock at $0.5349 per warrant, with an exercise price of $0.0001 per share.
- The offering is expected to generate approximately $40.0 million in gross proceeds and is anticipated to close around February 13, 2026.
- The financing was led by existing investor Coastlands Capital and included participation from Gilead Sciences, Inc., OrbiMed, Perceptive Advisors, and other new and existing institutional investors.
- Xilio intends to use the net proceeds to advance the development of its product candidates and for working capital requirements and other general corporate purposes.
Feb 12, 2026, 2:34 AM
Xilio Therapeutics Announces Financial Updates and Board Chair Appointment
XLO
Guidance Update
Board Change
New Projects/Investments
- Xilio Therapeutics received $35.8 million in gross proceeds from Series B warrant exercises, contributing to an estimated $137.5 million in cash and cash equivalents as of December 31, 2025, which is anticipated to fund operations into the second quarter of 2027.
- Sara Bonstein was appointed chair of the board of directors, succeeding Paul Clancy, who retired.
- The company achieved a development milestone under its AbbVie agreement and nominated a development candidate for its wholly-owned masked T cell engager program targeting CLDN18.2.
Jan 8, 2026, 1:42 PM
Xilio Therapeutics Announces Q3 2025 Financial Results and Pipeline Updates
XLO
Earnings
Guidance Update
New Projects/Investments
- Xilio Therapeutics reported collaboration and license revenue of $19.1 million and a net loss of $16.3 million for the third quarter ended September 30, 2025.
- The company's cash and cash equivalents were $103.8 million as of September 30, 2025, and it anticipates a cash runway into the first quarter of 2027. This includes a $17.5 million development milestone payment received from Gilead in Q4 2025.
- Key pipeline updates include vilastobart demonstrating a 40% objective response rate (ORR) in specific metastatic colorectal cancer patients and efarindodekin alfa achieving a $17.5 million development milestone from Gilead.
- Xilio plans to submit an Investigational New Drug (IND) application for XTX501 in mid-2026 and for at least two masked T cell engager programs in 2027.
Nov 13, 2025, 12:35 PM
Xilio Therapeutics Announces Q3 2025 Financial Results and Pipeline Updates
XLO
Earnings
Guidance Update
New Projects/Investments
- Xilio Therapeutics reported a net loss of $16.3 million for the third quarter ended September 30, 2025, compared to $14.0 million for the same period in 2024.
- The company's cash and cash equivalents totaled $103.8 million as of September 30, 2025, an increase from $55.3 million at December 31, 2024, driven by collaboration payments and a public offering.
- Collaboration and license revenue significantly increased to $19.1 million for the quarter ended September 30, 2025, up from $2.3 million in the prior year period.
- Xilio anticipates its cash and cash equivalents, including a $17.5 million development milestone received in the fourth quarter of 2025, will fund operations into the first quarter of 2027.
- Key pipeline progress includes late-breaking Phase 2 data for vilastobart demonstrating a 40% objective response rate (ORR) in heavily pretreated MSS mCRC patients without liver metastases and high plasma tumor mutational burden , promising monotherapy anti-tumor activity for efarindodekin alfa , and plans to submit an IND application for XTX501 in mid-2026.
Nov 13, 2025, 12:30 PM
Xilio Presents Updated Clinical Data for Vilastobart and Pipeline Progress
XLO
Product Launch
New Projects/Investments
Guidance Update
- Xilio presented updated Phase 2 data for vilastobart in combination with atezolizumab for patients with MSS mCRC without liver metastases and high plasma TMB, achieving a 40% Overall Response Rate (ORR), as of November 7, 2025.
- The vilastobart combination demonstrated a differentiated safety and tolerability profile in Phase 2, with no Grade 5 treatment-related adverse events (TRAEs) and a low incidence of colitis (7% of patients).
- The company's pipeline also includes Efarindodekin Alfa (XTX301), which showed promising Phase 1 efficacy and a well-tolerated safety profile, and Masked T cell engager programs with development candidates nominated for PSMA (Q3 2025) and CLDN18.2 (Q4 2025).
- Key anticipated milestones include reporting updated Phase 2 data for vilastobart in 1H 2026, IND submission for XTX501 in Mid 2026, and IND submissions for at least two masked T cell engager programs in 2027.
- Xilio maintains strategic partnerships with Roche, Gilead, and AbbVie for various programs, including co-funding, licensing options, and multi-program collaborations.
Nov 10, 2025, 9:30 PM
Xilio Therapeutics Presents Positive Velastigard Clinical Data and Pipeline Updates
XLO
New Projects/Investments
- Xilio Therapeutics presented positive Phase 2 clinical data for Velastigard in combination with Tislelizumab for microsatellite stable colorectal cancer (MSSCRC) at the SITC conference.
- In a biomarker-defined population with high plasma tumor mutational burden (TMB), Velastigard demonstrated a 40% overall response rate (ORR) in MSSCRC patients without liver metastases, a statistically significant correlation.
- Velastigard exhibited a differentiated safety profile with low systemic activation and a 7% rate of colitis, approximately half the incidence seen with systemically active anti-CTLA-4 combinations.
- The company is actively seeking a partner to develop Velastigard in combination with PD-1/PD-L1 or newer PD-1 bispecifics for MSSCRC and other tumor types.
- Xilio anticipates reporting additional Phase 2 data for Velastigard in MSSCRC in H1 2026, submitting an IND for XTX501 in mid-2026, and providing updates on masked T-cell engagers in early 2026.
Nov 10, 2025, 9:30 PM
Xilio Therapeutics Presents Positive Velastigard Clinical Data for MSSCRC
XLO
- Xilio Therapeutics presented new clinical data for Velastigard, its FC-enhanced tumor-activated anti-CTLA-4, in combination with Tislelizumab for microsatellite stable colorectal cancer (MSSCRC) at the SITC conference.
- The combination demonstrated a 40% Overall Response Rate (ORR) in heavily pretreated MSSCRC patients without liver metastases and with high plasma Tumor Mutational Burden (TMB) , a significant improvement over the 0-6% response rates of current standard-of-care therapies.
- Plasma TMB was identified as a statistically significant predictive biomarker for response, with approximately 55% of all MSSCRC patients having high plasma TMB.
- The safety profile of Velastigard in combination with Tislelizumab was favorable, showing minimal additional toxicity beyond Tislelizumab monotherapy, with a 7% incidence of colitis and a 5% discontinuation rate.
- Xilio is actively seeking a partner for Velastigard's development and plans to assess the appropriate regulatory path for this novel biomarker-driven strategy.
Nov 10, 2025, 9:30 PM
Xilio Therapeutics discusses SITC data updates for Vilastobart
XLO
New Projects/Investments
- Xilio Therapeutics presented new clinical data for Vilastobart in combination with Atezolizumab, demonstrating a 40% overall response rate (ORR) in late-line metastatic microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases and with high plasma tumor mutational burden (TMB).
- This 40% ORR represents a significant improvement over the 0%-6% response rate observed with current standard-of-care therapies in this patient population.
- Plasma-based TMB was identified as a predictive biomarker, with approximately 55% of MSS CRC patients having high plasma TMB, indicating a substantial addressable patient population.
- The combination demonstrated a differentiated safety profile, with a 7% incidence of colitis of any grade and a 5% discontinuation rate due to toxicity, which is lower than other anti-CTLA-4 combinations.
- Xilio plans to seek a partner for Vilastobart's development and assess the appropriate regulatory path for this novel biomarker-driven strategy.
Nov 10, 2025, 9:30 PM
Xilio Therapeutics Announces Positive Phase 2 Data for Vilastobart
XLO
New Projects/Investments
M&A
- Xilio Therapeutics announced positive late-breaking Phase 2 data for vilastobart in combination with atezolizumab in heavily pre-treated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without liver metastases and with high plasma tumor mutational burden (TMB).
- The study demonstrated a 40% objective response rate (ORR) in this patient population, with a statistically significant correlation between plasma TMB status and response.
- The company estimates that approximately 55% of patients with MSS CRC have high plasma TMB, representing a meaningful patient population who could benefit from this combination treatment.
- Vilastobart in combination with atezolizumab showed a generally well-tolerated safety profile, with treatment-related adverse events primarily Grade 1 or 2.
- Xilio is actively seeking a partner to further develop vilastobart in combination with PD-(L)1 or PD1-VEGF in MSS CRC and other tumor types.
Nov 7, 2025, 2:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more